Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial - ScienceDirect
Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease | Scientific Reports
Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study | Arthritis Research & Therapy | Full Text
Febuxostat Dosage Guide + Max Dose, Adjustments - Drugs.com
Pharmaceuticals | Free Full-Text | Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat
Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease - ACR Meeting Abstracts
Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management | NEJM Evidence
Low‐dose febuxostat exhibits a superior renal‐protective effect and non‐inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double‐centre, randomized, controlled study - Yang - 2022 -
Lesson: Gout and Hyperuricemia: Treatment Update and Pharmacist's Role
Kidney News : December 2017 9#12
Febuxostat - wikidoc
Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management | NEJM Evidence
Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia | SpringerLink
Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease - ACR Meeting Abstracts
Variations of serum uric acid and febuxostat dose across different... | Download Scientific Diagram
Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD Sarvepalli PS, Fatima M, Quadri AK, Taher AR, Habeeb A, Amreen F, Parveen BN, Rajaram K G -
![PDF] Therapeutic Potency of Febuxostat for Hyperuricemia in Patients with Chronic Kidney | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f8f35c9a28527099688c8822dfc437c8d7c15701/2-Table1-1.png "PDF] Therapeutic Potency of Febuxostat for Hyperuricemia in Patients with Chronic Kidney | Semantic Scholar")
PDF] Therapeutic Potency of Febuxostat for Hyperuricemia in Patients with Chronic Kidney | Semantic Scholar
A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout
Febuxostat Therapy for Patients with Gout and Stage 2–4 CKD: a Retrospective Study | SpringerLink
Study design. Febuxostat dose 40 or 80 mg; verinurad dose range 2.5-20 mg. | Download Scientific Diagram
Low‐dose febuxostat exhibits a superior renal‐protective effect and non‐inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double‐centre, randomized, controlled study - Yang - 2022 -
Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities | Nature Reviews Rheumatology
Low‐dose febuxostat exhibits a superior renal‐protective effect and non‐inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double‐centre, randomized, controlled study - Yang - 2022 -
